[ACCESSWIRE]
NEW YORK, NY / ACCESSWIRE / November 1, 2016 / Market Exclusive announces that Aegis Capital Corp has initiated coverage of Matinas BioPharma Holdings Inc. (OTCQB: MTNB), with a Buy rating and a 12-month price target of $8 per share.
In his investment summary, Aegis Capital analyst Robert LeBoyer wrote, "Matinas has developed a proprietary technology that we believe is a substantial advance in delivering drugs to their target tissues." Mr. LeBoyer summarizes, "The company has developed a drug delivery technology to make drugs orally available, more effective, and less toxic." He also highlights that Matinas' two clinical stage products, MAT2203 and MAT2501, are being developed under the FDA's Orphan, QIDP and Fast Track designations, allowing for the size and clinical trial duration to be less than for large, general population drugs.
In the report, Mr. LeBoyer explains why recent legislative changes are favorable for Matinas. Congress passed legislation known as the GAIN Act (Generating Antibiotic Incentives Now) in 2012 to encourage the development of new drugs for infectious diseases. This legislation provides regulatory benefits including accelerated approval with trials that are typically smaller and have shorter treatment periods. It also adds five additional years of additional market exclusivity to innovator drugs. Matinas' MAT2203 and MAT2501 are both eligible for the benefits of the GAIN Act.
About Market Exclusive
Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
SOURCE: Market Exclusive
